Ablation therapy for lung metastases in advanced liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of image-guided ablation therapy combined with systemic therapy for patients with advanced hepatocellular carcinoma (HCC) who have pulmonary oligometastasis. The approach aims to eliminate limited metastases, which may improve patient prognosis. By utilizing techniques such as microwave ablation, radiofrequency ablation, and cryoablation, the study seeks to provide clinical evidence for this minimally invasive treatment. The multicenter design allows for a broader assessment of outcomes across different patient populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. diagnosis of primary or recurrent HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;
2. presence of pulmonary oligometastasis;
3. metastases with limited five sites and no more two organs involved, with a maximum diameter of ≤5cm;
4. receipt of first-line systemic therapy for minimum of 3 months before ablation;
5. undergone locoregional treatments, including transarterial artery chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) were included;
6. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
7. no history of other malignancies.
8. life expectancy more than 3 months;
9. agreed to participated in this clinical trial;
10. Hemameba ≥3.0 x109/L, neutrophil ≥1.5x109/L, hemoglobin≥10.0 g/L, platelet≥100x 109/L, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml/min.

Exclusion Criteria:

1. intermediate HCC;
2. age \< 18 years or \> 75 years;
3. advanced HCC with more than five metastases;
4. no response to systemic therapy;
5. metastases size \> 5 cm;
6. life expectancy less than 3 months.

Where it's running

• Chinese PLA General hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Qunfang Zhou, MD
• Email: zhouqun988509@163.com
• Phone: 86 19868000115

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Stereotactic Ablative Radiotherapy for metastatic cancer treatment

  This study tests if starting stereotactic ablative radiotherapy right away helps people with newly diagnosed metastatic lung, colorectal, or prostate cancer live longer compared to waiting three months to start treatment.

  Recruiting Phase 3 Roswell Park Cancer Institute · Buffalo, New York · NCT06563388

• Ablation combined with lenvatinib and PD-1 inhibitor for advanced liver cancer with limited metastases

  This study is testing if combining a targeted treatment with a special type of therapy can help people with advanced liver cancer that has spread a little, to see if it improves their chances of living longer.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06550921

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• Urine VOC Test to Detect Lung Cancer in Never Smokers

  A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07871656

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.